GABAPENTIN AND PREGABALIN ABUSE AMONG EUROPAD SUBJECTS

J Iwanicki¹, M Hennessy¹, SG Severtson¹, K McBride^{1,} J Schwarz¹, N Scherbaum², D Hill³, M Guareschi⁴, RC Dart¹, I Maremmani⁴⁻⁵

¹Rocky Mountain Poison & Drug Center, Denver Health, Denver, CO, USA; ²LVR-Hospital Essen, Department of Addictive Behaviour and Addiction Medicine, Medical Faculty, University of Duisburg-Essen, Essen, Germany, EU; ³National Health Service Lanarkshire, Motherwell, Scotland, UK; ⁴Associazione per l'Utilizzo delle Conoscenze Neuroscientifiche a fini Sociali (AU-CNS), Pietrasanta, Italy, EU; 5Department of Neurosciences, Santa Chiara University Hospital, Pisa, Italy, EU

Background

- Gabapentin and pregabalin are widely used to treat neuropathic pain, seizure disorders, and anxiety disorders, and prescriptions have increased markedly over the past decade. However, these drugs also carry a potential for misuse.
- We describe gabapentin and pregabalin abuse among subjects seeking opioid treatment in the European Opioid Treatment Patient Survey (EUROPAD) Program.

Methods

- The European Opiate Addiction Treatment Association (Europad) and the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®) System treatment program is a cooperative effort between the Associazione per l'Utilizzo delle Conoscenze Neuroscientifiche a fini Sociali and the Rocky Mountain Poison & Drug Center, and is comprised of 11 participating European opioid treatment programs.
- Participating programs survey abuse of prescription drugs among patients entering drug dependence treatment programs.
- Data from 4th quarter 2014 through 1st quarter 2017 were analyzed. Descriptive statistics on demographic and co-endorsement variables for respondents who endorsed abuse of gabapentin and pregabalin ("GABA-Users" in figure) are presented.

| DENVER |
|--------------------|
| HEALTH. |
| —— est. 1860 —— |
| FOR LIFE'S JOURNEY |
| |







France

The RADARS System is supported by subscriptions from pharmaceutical manufacturers, government and non-government agencies for surveillance, research and reporting services. RADARS System is the property of Denver Health and Hospital Authority, a political subdivision of the State of Colorado. Denver Health retains exclusive ownership of all data, databases and systems. Subscribers do not participate in data collection nor do they have access to the raw data.

| Table 1. Demographics | | | |
|------------------------------------|--------------|--------------|--|
| | Gabapentin | Pregabalin | |
| Total | 79 | 75 | |
| | | | |
| Average Age (Std.) | 33.62 (8.7) | 34.91 (8.66) | |
| Avg. Age at First Treatment (Std.) | 24.08 (8.26) | 24.91 (8.00) | |
| GENDER | | | |
| Male | 51 (64.6) | 49 (65.3) | |
| Female | 28 (35.4) | 26 (34.7) | |
| Country | | | |
| France | 1 (1.3) | 5 (6.7) | |
| Germany | 32 (40.5) | 13 (17.3) | |
| Italy | 1 (1.3) | 1 (1.3) | |
| Norway | 7 (8.9) | 8 (10.7) | |
| Spain | 1 (1.3) | 4 (5.3) | |
| UK | 37 (46.8) | 44 (58.7) | |
| | Т | | |
| Primary Drug: Heroin | 54 (68.4) | 59 (78.7) | |
| Primary Drug: Oxycodone | 2 (2.5) | 4 (5.3) | |
| | | | |
| Health Care Professional | 4 (5.1) | 0 (0.0) | |
| Chronic Pain | 22 (27.8) | 26 (34.7) | |
| Prior Overdose | 39 (49.4) | 33 (44.0) | |
| Avg. Endorsed APIs (Std.) | 5.73 (2.70) | 6.09 (2.72) | |
| | | | |


Germany

Results

- From 4th quarter 2014_through 1st quarter 2017, 1865 respondents completed the survey. 79 respondents (4.2%) endorsed past 90-day gabapentin abuse, and 75 (4%) endorsed pregabalin abuse (Table 1).
- Heroin was the most common primary drug of abuse (68.4% of gabapentin respondents, 78.7% of pregabalin respondents).
- Respondents reporting past 90-day abuse of gabapentin and pregabalin endorsed abuse of 5.73 (SD 2.70) and 6.09 (SD 2.72) Active Pharmaceutical Ingredients (API) on average per person respectively (Figure 1).
- Reports of pregabalin or gabapentin as the respondent's primary drug of abuse were rare (3 and 1 respondents, respectively).

Conclusions

- Among EUROPAD Program subjects, gabapentin and pregabalin abuse are most often reported by respondents who endorse polysubstance abuse.
- Endorsement of gabapentin and pregabalin as primary drugs of abuse is rare.



Norway

Spain

Italy